FOR IMMEDIATE RELEASE|
WEDNESDAY, JUNE 11, 2003
TDD (202) 514-1888
PHARMACEUTICAL COMPANY, DEY, INC. TO PAY U.S. & TEXAS $18.5 MILLION TO SETTLE ALLEGATIONS OF MEDICAID FRAUD
WASHINGTON, D.C.- Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, has agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud, the Justice Department and the Attorney General of the State of Texas, announced today.
The government alleged that the company submitted false pricing information and caused providers to submit fraudulently inflated reimbursement claims to the state and federally funded Texas Medicaid program. The United States claimed the Napa, California-based company submitted false pricing information to the Texas Vendor Drug Program, which resulted in inflated reimbursement for the Dey drugs at issue, which are primarily used to treat asthma and other respiratory conditions.
"The Medicaid program was created to help ensure that those least able to afford healthcare receive medical treatment - not to enrich drug companies," said Robert D. McCallum, Jr., Assistant Attorney General for the Justice Departmentís Civil Division. "The reporting of false pricing information by certain drug manufacturers has adversely impacted not only the federal health care programs, but also our most vulnerable citizens."
The Civil Medicaid Fraud Section of the Texas Attorney General's Office sued Dey and two other drug manufacturers in 2000 as part of its ongoing effort to combat Medicaid Fraud in Texas. The remaining defendants are scheduled for trial in August of this year.
Dey, a wholly owned subsidiary of Merck KGaA in Germany, reached the agreement with the Justice Department, the Office of Inspector General for the Department of Health and Human Services and Texas Attorney General Greg Abbott. The United States is continuing to investigate Dey's activities with respect to other states' Medicaid programs.